Apolipoprotein A-I mimetic peptides

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 481-486

  Hovingh, G K ^a   Bochem, Andrea E ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

apoliporotein A I; atherosclerosis; high density lipoprotein cholesterol; mimetic peptides

Indexed keywords

18A PEPTIDE; 5F PEPTIDE; APOLIPOPROTEIN A1; ATI 5261; DEXTRO 4F PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVO 4F PEPTIDE; PEPTIDOMIMETIC AGENT; PLACEBO; PRAVASTATIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENTIATION; GRAFT REJECTION; HUMAN; IN VIVO STUDY; LIVER FIBROSIS; MEDICAL LITERATURE; METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SEPTICEMIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETICS; CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL, HDL; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MICE; PEPTIDES; RATS; RISK FACTORS;

EID: 78650306223     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283404507     Document Type: Review

References (56)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II: In atherosclerosis and related conditions. Am J Med 1951; 11:480-493.
2. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
3. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
4. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58:342-374.
5. Fielding CJ, Fielding PE. Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. Med Clin North Am 1982; 66:363-373.
6. Suc I, Escargueil-Blanc I, Troly M, et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997; 17:2158-2166.
7. Puranik R, Bao S, Nobecourt E, et al. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008; 196:240-247.
8. Deguchi H, Pecheniuk NM, Elias DJ, et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112:893-899.
9. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
10. Nissen SE, TsunodaT, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
11. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008; 103:1084-1091.
12. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356: 1620-1630.
13. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
14. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316.
15. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30:151-155.
16. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51:2199-2211.
17. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res 2010; 51:2058-2073.
18. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-1821.
19. Moore RE, Kawashiri MA, Kitajima K, et al. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 2003; 23:1914-1920.
20. Voyiaziakis E, Goldberg IJ, Plump AS, et al. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J Lipid Res 1998; 39:313-321.
21. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265-267.
22. Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94:713-717.
23. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15:1882-1888.
24. Hovingh GK, BrownlieA, Bisoendial RJ, et al.A novel apoA-I mutation (L1 78P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44:1429-1435.
25. Anantharamaiah GM, Jones JL, Brouillette CG, et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985; 260:10248-10255.
26. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 1994; 94:1698-1705.
27. Remaley AT, Thomas F, Stonik JA, et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003; 44:828-836.
28. Navab M, Anantharamaiah GM, HamaS, et al. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290-292.
29. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481-1494.
30. Van Lenten BJ, Wagner AC, Jung CL, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 2008; 49:2302-2311.
31. Wool GD, Reardon CA, Getz GS. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially antiatherogenic properties. J Lipid Res 2008; 49:1268-1283.
32. D'Souza W, Stonik JA, Murphy A, et al. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ Res 2010; 107:217-227.
33. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002; 41:2089-2096.
34. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42:545-552.
35. Tabet F, Remaley AT, Segaliny AI, et al. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 2010; 30:246-252.
36. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of prebeta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macro-phages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
37. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1426-1432.
38. Bielicki JK, Zhang H, Cortez Y, et al. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010; 51:1496-1503.
39. Vaziri ND, Bai Y, Yuan J, et al. ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta. Am J Nephrol 2010; 32:201-211.
40. Vaziri ND, Kim H, Moradi H, et al. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice. Nephrol Dial Transplant 2010. [Epub ahead of print]
41. Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005; 11:97-103.
42. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90:12040-12044.
43. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-2756.
44. Dai L, Datta G, Zhang Z, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 2010; 51:2695-2705.
45. Gupta H, Dai L, Datta G, et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005; 97:236-243.
46. Hsieh GR, Schnickel GT, Garcia C, et al. Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007; 84:238-243.
47. Schnickel GT, Hsieh GR, Kachikwu EL, et al. Cytoprotective gene HO-1 and chronic rejection in heart transplantation. Transplant Proc 2006; 38:3259-3262.
48. Woo JM, Lin Z, Navab M, et al. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 2010; 12:R93.
49. Weihrauch D, Xu H, Shi Y, et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007; 293:H1432-H1441.
50. Peterson SJ, Drummond G, Kim DH, et al. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 2008; 49:1658-1669.
51. Ruan X, Li Z, Zhang Y, et al. Apolipoprotein A-I possesses an antiobesity effect associated with increase of energy expenditure and upregulation of UCP1 in brown fat. J Cell Mol Med 2010. [Epub ahead of print]
52. Buga GM, Navab M, Imaizumi S, et al. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol 2010; 30:283-289.
53. Handattu SP, Garber DW, Monroe CE, et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009; 34:525-534.
54. DeLeve LD, Wang X, Kanel GC, et al. Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol 2008; 173:993-1001.
55. Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharma- codynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008; 49:1344-1352.
56. Navab M, Ruchala P, Waring AJ, et al. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res 2009; 50:1538-1547.